Background
==========

HIV-infected patients harbouring a lamivudine-resistant virus, seem to take benefit from a continued lamivudine monotherapy, versus combined antiretroviral treatment (cART) interruption, since a reduced HIV replication is selected by the maintenance of lamivudine-related M184 mutation. The mid-term outcome of isolated lamivudine therapy in multi-drug-resistant patients with very restricted therapeutic options, waiting for novel drug classes, is reported.

Methods
=======

Six patients aged 23-49 years (4 males and 2 females, one of them with perinatal infection), with HIV disease treated since 13.8 ± 6.2 years with 10.3 ± 4.7 therapeutic lines, experienced repeated virological-immunological failures due to an extensive HIV genotype resistance, which finally led to a complete 3-class resistance, and no residual therapeutic options, when excluding the use of a fusion/integrase/co-receptor inhibitors, without the possibility to optimize the therapeutic background. A concurrent toxicity was also present:combined lipodistrophy syndrome, dyslipidemia, and insulin resistance (3,2, and one patients, respectively).

Results
=======

At the time of lamivudine monotherapy initiation, the median viremia was 36,000 HIV-RNA copies/mL, while the median CD4+ count was 344 cells/μL. Despite a previous diagnosis of AIDS in 4/6 patients, at the time of therapeutic switch the clinical situation was stable. During the monthly follow-up with lamivudine monotherapy, ranging from 8 to 24 months (mean 9.9 ± 5.2) months, no HIV-associated signs-symptoms occurred, previous cART-associated laboratory toxicity significantly ameliorated, and no significant differences were found as to virological-immunological markers of HIV disease. A fluctuating viremia was noticed in all cases, with a median value at the end of follow-up of 44,000 HIV-RNA copies/mL, while no significant loss of CD4+ count occurred (median final levels:322 cells/μL). Two-four nucleos(t)ide mutations, and 2-5 protease mutations were deselected during the follow-up, but the M184 mutation remained. All these patients were allowed to re-introduce a cART with novel drug classes, according to the availability of an optimized therapeutic background in the subsequent months.

Discussion
==========

When extensive HIV resistance does not leave therapeutic options, lamivudine monotherapy performed with a strict monitoring in clinically stable patients with no compromised virological-immunological figures, is a potentially safe choice. Waiting for the novel cART associations, the exploitment of lamivudine resistance on HIV replication-fitness represents an ultimate therapeutic approach to these difficult-to-manage subjects.
